887 related articles for article (PubMed ID: 2208789)
1. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
2. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
5. Effect of macrophages on interleukin-2 (IL-2)- and IL-4-induced murine lymphokine-activated killer activity.
Tunru IS; Suzuki H; Yano S
Int J Cancer; 1991 Jun; 48(4):568-73. PubMed ID: 2045201
[TBL] [Abstract][Full Text] [Related]
6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
7. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
8. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
9. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
10. Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.
Stewart LS; Sewell HF; Thomson AW
Clin Exp Immunol; 1990 Mar; 79(3):416-23. PubMed ID: 2317946
[TBL] [Abstract][Full Text] [Related]
11. Effect of ASTA-Z 7575 (INN Maphosphamide) on human lymphokine-activated killer cell induction.
Singh KP; Gupta RK; Shau H; Ray PK
Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):525-38. PubMed ID: 8301017
[TBL] [Abstract][Full Text] [Related]
12. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
13. Isolation of human NK cells and generation of LAK activity.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
[TBL] [Abstract][Full Text] [Related]
14. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
15. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
16. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
Pope BL; Chourmouzis E; Victorino L; MacIntyre JP; Capetola RJ; Lau CY
J Immunol; 1993 Sep; 151(6):3007-17. PubMed ID: 8376766
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
Gazit Z; Kedar E
Cancer Immunol Immunother; 1994 Apr; 38(4):243-52. PubMed ID: 8168119
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer (LAK) activity to cultured rat kidney parenchymal components in vitro.
Nietosvaara Y; Renkonen R; Mattila P; Häyry P
Transpl Int; 1989 Dec; 2(4):209-13. PubMed ID: 2627263
[TBL] [Abstract][Full Text] [Related]
19. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
Donskov F; Basse PH; Hokland M
Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]